Blincyto 38.5mg (Blinatumomab Vials) 38.5mg

Blincyto 38.5mg is a prescription biologic used in cancer therapy. This vial contains blinatumomab, a targeted treatment option for certain blood cancers. Find reliable information on uses, effects, and handling here.

Strength

38.5mg

Manufacturer / TM Owner

BOEHRINGER INGELHEIM

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Blinatumomab, the active ingredient in Blincyto 38.5mg, is used to treat specific types of blood cancer, including acute lymphoblastic leukemia. It works by helping the immune system target cancer cells more effectively. This medication is typically prescribed when other treatments have not been successful or as part of a targeted therapy approach.

Side Effects

Blincyto 38.5mg is administered under medical supervision, and its effects are closely monitored. Patients may experience changes in their condition as the treatment progresses. Common effects include immune system responses as the body reacts to the medication.

Precautions & Warnings

Blincyto 38.5mg should only be handled and administered by healthcare professionals. It requires careful storage and preparation to maintain its effectiveness. Patients should follow their healthcare provider’s instructions closely and report any unusual symptoms during treatment.

Avoid Interactions

Blinatumomab may interact with other medications, including those that affect the immune system. Patients should inform their healthcare provider about all medications they are taking, including over-the-counter drugs and supplements. Alcohol and certain foods may also interact with the treatment process.

Frequently Asked Questions

Blincyto 38.5mg is used to treat certain types of blood cancer, such as acute lymphoblastic leukemia.

It is administered by healthcare professionals as an intravenous infusion.

Side effects may include fever, fatigue, and immune system reactions.

Patients should consult their healthcare provider before taking other medications during treatment.

This medication is prescribed based on individual health conditions and should only be used under medical supervision.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.